Project Number: 5450-51000-036-02
Project Type: Reimbursable

Start Date: Sep 01, 2005
End Date: Aug 31, 2010

Objective:
Develop algorithm relating increase in stable plasma Se level to that at baseline and level of supplemental Se.

Approach:
Conduct a randomized, double-blind, intervention study will be conducted with healthy men (120) and women (120) randomized to 0, 50, 100, or 200 ug Se/day (as L-selenomethionine) administered in daily oral doses. Fasting blood samples and urine samples will be drawn two wks prior to and periodically throughout the 1-yr study. The following measurements will be made: Se, homocysteine, vitamin B12 and folate in plasma; Se and 8a-deoxyquanosine in urine; DNA damage and allelic variants of Se-dependent enzymes in lymphocytes. Results will be used to compute the relationship of final-plateau plasma (9-12 mos.) Se concentration as a function of baseline (0 mos.) Se level, Se dose, metabolic body size and urinary Se, as well as outcomes related to carcinogenesis.